The scope of the collaboration includes manufacturing process development, IND-enabling pharmacology and toxicology studies, and production of ATI-1013 for use in clinical trials.
All programme results and materials will be provided to ATI for further development.
ATI-1013 is a human, monoclonal antibody that sequesters nicotine in the blood. Studies in rodents show that following an injection of nicotine, ATI-1013 reduces nicotine levels in the brain by more than 90% which, in turn, reduces nicotine's addictive effects.
The clinical aim is to help smokers at elevated risk of developing smoking-induced lung cancer to stop or substantially reduce smoking.
This collaboration will be managed through NCI's Division of Cancer Prevention PREVENT Cancer Preclinical Drug Development Program, a peer reviewed program which supports the best ideas in preclinical cancer prevention agent development.
In partnership with ATI, PREVENT will fund and manage contract resources for the manufacturing, pre-IND development, and filing of an IND for ATI-1013. The programme will be progressed based on achievement of interim milestones.
Antidote Therapeutics, Inc. is a biotechnology company with a portfolio of first-in-class nicotine-blocking drugs to treat diseases caused or worsened by nicotine.
In addition to ATI-1013, the company has other product candidates that neutralize or eliminate nicotine in the blood.
Results of a preclinical, proof-of-concept study of its nicotine-degrading enzyme, NicA2, were published recently in the journal, BMC biotechnology, and validate the approach of using a nicotine-degrading enzyme to treat nicotine addiction and prevent relapse.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review